Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

NCT04902040 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped PI requested.

Conditions

Advanced Bladder Carcinoma
Advanced Lung Non-Small Cell Carcinoma
Advanced Malignant Solid Neoplasm
Advanced Melanoma
Advanced Merkel Cell Carcinoma
Advanced Renal Cell Carcinoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage III Merkel Cell Carcinoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage IV Merkel Cell Carcinoma AJCC v8
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage III Merkel Cell Carcinoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Pathologic Stage IV Cutaneous Melanoma AJCC v8
Pathologic Stage IV Merkel Cell Carcinoma AJCC v8
Stage III Bladder Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Stage III Renal Cell Cancer AJCC v8
Stage IIIA Bladder Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Bladder Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Stage IV Bladder Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
Stage IVA Bladder Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Bladder Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

BIOLOGICAL: Atezolizumab
DRUG: Avelumab
BIOLOGICAL: Durvalumab
BIOLOGICAL: Nivolumab
BIOLOGICAL: Pembrolizumab
DRUG: Plinabulin
RADIATION: Radiation Therapy

Sponsor

M.D. Anderson Cancer Center